ArticleBMJ open2025

NEOadjuvant Dendritic cell therapy added to first line standard of care in advanced epithelial Ovarian Cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I/II trial in the Netherlands.

Bouke Koeneman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.